Key Insights

Highlights

Success Rate

87% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

8.3%

3 terminated out of 36 trials

Success Rate

87.0%

+0.5% vs benchmark

Late-Stage Pipeline

6%

2 trials in Phase 3/4

Results Transparency

10%

2 of 20 completed with results

Key Signals

2 with results87% success

Data Visualizations

Phase Distribution

28Total
Not Applicable (15)
P 1 (4)
P 2 (7)
P 3 (1)
P 4 (1)

Trial Status

Completed20
Unknown4
Recruiting4
Terminated3
Enrolling By Invitation2
Active Not Recruiting1

Trial Success Rate

87.0%

Benchmark: 86.5%

Based on 20 completed trials

Clinical Trials (36)

Showing 20 of 20 trials
NCT06511050Phase 1Recruiting

Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

NCT04542161Phase 2Recruiting

Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

NCT04740736Not ApplicableCompletedPrimary

Cardiovascular Analysis of PEM

NCT05236465Not ApplicableRecruiting

A 3-day Course for CFS/ME

NCT05167227Not ApplicableActive Not Recruiting

Does a Technology Enabled Multi-disciplinary Team-based Care Model for the Management of Long COVID and Other Fatiguing Illnesses Improve Clinical Care of Patients and Represent a Sustainable Approach Within a Federally Qualified Health Center?

NCT04031469Suspended

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

NCT05059184CompletedPrimary

Long-term Sequelae of COVID-19 (Myalgic Encephalomyelitis): An International Cross-Sectional Study

NCT04100915WithdrawnPrimary

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in ME/CFS

NCT05741112Not ApplicableRecruiting

The Long COVID-19 Wearable Device Study

NCT04622293Phase 4Completed

A Trial of Solriamfetol in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

NCT03254823CompletedPrimary

Autoimmunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

NCT05273372Not ApplicableCompletedPrimary

RESTORE ME -- RCT of Oxaloacetate on Improving Fatigue in ME/CFS

NCT05664711Phase 1Completed

Effect of Stellate Ganglion Block on ME/CFS

NCT06257420Enrolling By InvitationPrimary

Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions

NCT06145867Not ApplicableEnrolling By InvitationPrimary

A Feasibility Study: Assessing Photobiomodulation in Myalgic Encephalomyelitis

NCT01156922Phase 2Terminated

B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome

NCT03691987Phase 2Completed

The Comeback Study

NCT04026425Not ApplicableCompletedPrimary

Analysis of Post-exertional Malaise Using a Two-day CPET in People With ME/CFS

NCT05196529Not ApplicableCompletedPrimary

Inspiratory Muscle Training in ME/CFS and COVID-19 Survivors

NCT04301609Not ApplicableCompleted

Clinical Trial to Assess the Improvement of Fatigue, Sleep Problems, Anxiety / Depression, Neurovegetatives Alterations and Quality of Life After the Administration of ImmunoVita® in Chronic Fatigue Syndrome Patients

Scroll to load more

Research Network

Activity Timeline